ESR1 and breast carcinoma: The recent EBCTG meta-analysis of randomized trials of tamoxifen efficacy identified a slight trend for PR expression to be associated with benefit from tamoxifen therapy in ER- breast cancer; although this result did not reach statistical significance [14].